Clene Inc. (CLNN)

NASDAQ: CLNN · IEX Real-Time Price · USD
0.425
+0.001 (0.21%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.

In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.

The company is headquartered in Salt Lake City, Utah.

Clene Inc.
Clene logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 82
CEO Robert Etherington MBA

Contact Details

Address:
6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121
United States
Phone 801-676-9695
Website clene.com

Stock Details

Ticker Symbol CLNN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001822791
CUSIP Number 185634102
ISIN Number US1856341029
Employer ID 85-2828339
SIC Code 2834

Key Executives

Name Position
Robert Etherington MBA Chief Executive Officer, President and Director
Morgan R. Brown CPA, M.B.A. Chief Financial Officer
Mark G. Mortenson ESQ. Chief Science Officer
Jerry Miraglia J.D. General Counsel and Corporate Secretary
Michael T. Hotchkin Chief Development Officer
Mary Anne Mcneil Head of Human Resources
Dr. Benjamin M. Greenberg M.D., M.H.S. Head of Medical

Latest SEC Filings

Date Type Title
Mar 13, 2024 8-K Current Report
Mar 13, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Jan 8, 2024 8-K Current Report